Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future

  • Jeon, Ga Won (Department of Pediatrics, Inje University Busan Paik Hospital, Inje University College of Medicine)
  • Received : 2018.10.16
  • Accepted : 2019.02.08
  • Published : 2019.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Following the first successful trial of surfactant replacement therapy for preterm infants with respiratory distress syndrome (RDS) by Fujiwara in 1980, several animal-derived natural surfactants and synthetic surfactants have been developed. Synthetic surfactants were designed to overcome limitations of natural surfactants such as cost, immune reactions, and infections elicited by animal proteins contained in natural surfactants. However, first-generation synthetic surfactants that are protein-free have failed to prove their superiority over natural surfactants because they lack surfactant protein (SP). Lucinactant, a second-generation synthetic surfactant containing the SP-B analog, was better or at least as effective as the natural surfactant, suggesting that lucinactant could act an alternative to natural surfactants. Lucinactant was approved by the U. S. Food and Drug Administration in March 2012 as the fifth surfactant to treat neonatal RDS. CHF5633, a second-generation synthetic surfactant containing SP-B and SP-C analogs, was effective and safe in a human multicenter cohort study for preterm infants. Many comparative studies of natural surfactants used worldwide have reported different efficacies for different preparations. However, these differences are believed to due to site variations, not actual differences. The more important thing than the composition of the surfactant in improving outcome is the timing and mode of administration of the surfactant. Novel synthetic surfactants containing synthetic phospholipid incorporated with SP-B and SP-C analogs will potentially represent alternatives to natural surfactants in the future, while improvement of treatment modalities with less-invasive or noninvasive methods of surfactant administration will be the most important task to be resolved.

Keywords

References

  1. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;1:55-9. https://doi.org/10.1016/S0140-6736(02)95344-4
  2. Fujiwara T, Konishi M, Chida S, Okuyama K, Ogawa Y, Takeuchi Y, et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group. Pediatrics 1990;86:753-64.
  3. Parra E, Perez-Gil J. Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem Phys Lipids 2015;185:153-75. https://doi.org/10.1016/j.chemphyslip.2014.09.002
  4. Agassandian M, Mallampalli RK. Surfactant phospholipid metabolism. Biochim Biophys Acta 2013;1831:612-25. https://doi.org/10.1016/j.bbalip.2012.09.010
  5. Rudiger M, Kolleck I, Putz G, Wauer RR, Stevens P, Rustow B. Plasmalogens effectively reduce the surface tension of surfactant-like phospholipid mixtures. Am J Physiol 1998;274(1 Pt 1):L143-8.
  6. Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res 2017;81:240-8. https://doi.org/10.1038/pr.2016.203
  7. Moya F. Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials. J Perinatol 2009;29 Suppl 2:S23-8. https://doi.org/10.1038/jp.2009.26
  8. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001;(2):CD000144.
  9. Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2015;8:CD000144.
  10. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100:31-8. https://doi.org/10.1542/peds.100.1.31
  11. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21:109-19. https://doi.org/10.1055/s-2004-823779
  12. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol 2009;29 Suppl 2:S38-43. https://doi.org/10.1038/jp.2009.31
  13. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011;128:e1588-95. https://doi.org/10.1542/peds.2011-1395
  14. Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr 2013;163:955-60.e1. https://doi.org/10.1016/j.jpeds.2013.04.053
  15. Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Rojas-Reyes MX. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2015;(12):CD010249.
  16. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991;254:566-8. https://doi.org/10.1126/science.1948032
  17. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005;115:1018-29. https://doi.org/10.1542/peds.2004-2183
  18. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005;115:1030-8. https://doi.org/10.1542/peds.2004-2231
  19. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007;119:e1361-70. https://doi.org/10.1542/peds.2006-0149
  20. Moya F, Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol 2007;34:145-77. https://doi.org/10.1016/j.clp.2006.12.005
  21. Jordan BK, Donn SM. Lucinactant for the prevention of respiratory distress syndrome in premature infants. Expert Rev Clin Pharmacol 2013;6:115-21. https://doi.org/10.1586/ecp.12.80
  22. Piehl E, Fernandez-Bustamante A. Lucinactant for the treatment of respiratory distress syndrome in neonates. Drugs Today (Barc) 2012;48:587-93. https://doi.org/10.1358/dot.2012.48.9.1835160
  23. Sato A, Ikegami M. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung. PLoS One 2012;7:e39392. https://doi.org/10.1371/journal.pone.0039392
  24. Sweet DG, Turner MA, Stranak Z, Plavka R, Clarke P, Stenson BJ, et al. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 2017;102:F497-503. https://doi.org/10.1136/archdischild-2017-312722
  25. Jeon GW, Oh M, Sin JB. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study. Yonsei Med J 2015;56:433-9. https://doi.org/10.3349/ymj.2015.56.2.433
  26. Moya F, Javier MC. Myth: all surfactants are alike. Semin Fetal Neonatal Med 2011;16:269-74. https://doi.org/10.1016/j.siny.2011.03.006
  27. Lopez E, Gascoin G, Flamant C, Merhi M, Tourneux P, Baud O, et al. Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future? BMC Pediatr 2013;13:165. https://doi.org/10.1186/1471-2431-13-165
  28. Mahmoud RA, Roehr CC, Schmalisch G. Current methods of noninvasive ventilatory support for neonates. Paediatr Respir Rev 2011;12:196-205. https://doi.org/10.1016/j.prrv.2010.12.001
  29. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;358:700-8. https://doi.org/10.1056/NEJMoa072788
  30. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970-9. https://doi.org/10.1056/NEJMoa0911783
  31. Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011;128:e1069-76. https://doi.org/10.1542/peds.2010-3848

Cited by

  1. Trends of Mortality, Time, and Causes of Death in Preterm Infants vol.30, pp.4, 2019, https://doi.org/10.14734/pn.2019.30.4.221
  2. Practical considerations when administering surfactants to preterm infants with respiratory distress syndrome vol.62, pp.12, 2019, https://doi.org/10.3345/kjp.2019.00374
  3. Risk Factors and Neonatal Outcomes of Patent Ductus Arteriosus Ligation in Preterm Infants in a Single Center over 6 Years vol.31, pp.4, 2020, https://doi.org/10.14734/pn.2020.31.4.191
  4. Phosphatidylglycerol and surfactant: A potential treatment for COVID-19? vol.144, 2019, https://doi.org/10.1016/j.mehy.2020.110277
  5. Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2 vol.10, 2019, https://doi.org/10.1038/s41598-020-66448-1
  6. Alveolar lipids in pulmonary disease. A review vol.19, pp.1, 2019, https://doi.org/10.1186/s12944-020-01278-8
  7. Novel predictor markers for early differentiation between transient tachypnea of newborn and respiratory distress syndrome in neonates vol.35, 2019, https://doi.org/10.1177/20587384211000554
  8. The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution vol.14, 2019, https://doi.org/10.2174/1874467214666210208114439
  9. The Inhibitory Effect of Curosurf® and Alveofact® on the Formation of Neutrophil Extracellular Traps vol.11, 2019, https://doi.org/10.3389/fimmu.2020.582895
  10. Hypoxia-mediated alterations in pulmonary surfactant protein expressions: Beneficial effects of quercetin prophylaxis vol.291, 2019, https://doi.org/10.1016/j.resp.2021.103695
  11. Comparative efficacy and safety of late surfactant preparations: a retrospective study vol.41, pp.11, 2019, https://doi.org/10.1038/s41372-021-01142-2
  12. Surfactant protein C is associated with perineuronal nets and shows age-dependent changes of brain content and hippocampal deposits in wildtype and 3xTg mice vol.118, 2019, https://doi.org/10.1016/j.jchemneu.2021.102036
  13. Surfaxin attenuates PM2.5-induced airway inflammation via restoring surfactant proteins in rats exposed to cigarette smoke vol.203, 2022, https://doi.org/10.1016/j.envres.2021.111864